Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
8
|
pubmed:dateCreated |
1998-9-3
|
pubmed:abstractText |
IL-12 has been shown to be involved in the pathogenesis of Th1-mediated autoimmune diseases, but its role in antibody-mediated autoimmune pathologies is still unclear. We investigated the effects of exogenous and endogenous IL-12 in experimental autoimmune myasthenia gravis (EAMG). EAMG is an animal model for myasthenia gravis, a T cell-dependent, autoantibody-mediated disorder of neuromuscular transmission caused by antibodies to the muscle nicotinic acetylcholine receptor (AChR). Administration of IL-12 with Torpedo AChR (ToAChR) to C57BL/6 (B6) mice resulted in increased ToAChR-specific IFN-gamma production and increased anti-ToAChR IgG2a serum antibodies compared with B6 mice primed with ToAChR alone. These changes were associated with earlier and greater neurophysiological evidence of EAMG in the IL-12-treated mice, and reduced numbers of AChR. By contrast, when IL-12-deficient mice were immunized with ToAChR, ToAChR-specific Th1 cells and anti-ToAChR IgG2a serum antibodies were reduced compared to ToAChR-primed normal B6 mice, and the IL-12-deficient mice showed almost no neurophysiological evidence of EAMG and less reduction in AChR. These results indicate an important role of IL-12 in the induction of an antibody-mediated autoimmune disease, suggest that Th1-dependent complement-fixing IgG2a anti-AChR antibodies are involved in the pathogenesis of EAMG, and help to account for the lack of correlation between anti-AChR levels and clinical disease seen in many earlier studies.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0014-2980
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
28
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2487-97
|
pubmed:dateRevised |
2008-11-21
|
pubmed:meshHeading |
pubmed-meshheading:9710226-Animals,
pubmed-meshheading:9710226-Disease Models, Animal,
pubmed-meshheading:9710226-Electromyography,
pubmed-meshheading:9710226-Female,
pubmed-meshheading:9710226-Humans,
pubmed-meshheading:9710226-Immunoglobulin G,
pubmed-meshheading:9710226-Interferon-gamma,
pubmed-meshheading:9710226-Interleukin-12,
pubmed-meshheading:9710226-Male,
pubmed-meshheading:9710226-Mice,
pubmed-meshheading:9710226-Mice, Inbred C57BL,
pubmed-meshheading:9710226-Myasthenia Gravis,
pubmed-meshheading:9710226-Neuromuscular Junction,
pubmed-meshheading:9710226-Receptors, Cholinergic,
pubmed-meshheading:9710226-Th1 Cells,
pubmed-meshheading:9710226-Torpedo
|
pubmed:year |
1998
|
pubmed:articleTitle |
IL-12 is involved in the induction of experimental autoimmune myasthenia gravis, an antibody-mediated disease.
|
pubmed:affiliation |
Department of Biotechnology, San Raffaele Hospital, San Raffaele Scientific Institute, Milan, Italy.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|